Bone Scan: Clinical Trials

3 trials of Bone Scan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Terminated 3
Phase 22Terminated 2

Follow Bone Scan: new trials by email Literature Review of Bone Scan trials Research Report on Bone Scan

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 1TerminatedEmory University42023-08-032025-09-15
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)452016-05-092026-08-13
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Enzalutamide, Ribociclib, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 1 / Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University522015-12-012026-04-22

Conditions studied

Prostatic Neoplasms (3)  ·  Carcinoma, Transitional Cell (1)  ·  Lung Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Emory University (1)  ·  National Cancer Institute (NCI) (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)

Countries

United States (3)

Top investigators

Anish Thomas, M.D. (1)  ·  Bassel Nazha, MD, MPH (1)  ·  William Kevin Kelly, MD (1)

Results publications

PMID 32897402, PMID 42820295

NIH funding

P30CA138292 (1)